Clinical Trial Update: Evaluation of the Safety and Immune Response of Five Admixtures of a Tetravalent Dengue Virus Vaccine [Phase 1]

View source ↗

Summary

Phase 1 trial evaluating safety and immune response of five admixtures of a tetravalent dengue virus vaccine. The study status is completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Dengue

Drugs mentioned

• Tetravalent dengue virus vaccine (investigational)

Snippet

Sponsor: National Institute of Allergy and Infectious Diseases (NIAID) | Conditions: Dengue | Phase 1 | Status: COMPLETED